9.2  0.28 (3.14%)		10-30 16:00
Open: 8.64 High: 9.3 Volume: 27,883		Pre. Close: 8.92 Low: 8.4 Market Cap: 54(M)

Short term
Mid term
Targets	6-month :	12.3	1-year :	13.85
Resists	First :	10.53	Second :	11.85
Pivot price	9.61
Supports	First :	8.39	Second :	6.98
MAs	MA(5) :	9.03	MA(20) :	9.82
	MA(100) :	10.36	MA(250) :	11.21
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	18.2	D(3) :	11.8
RSI	RSI(14): 35.3
52-week	High :	14.76	Low :	8.39

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DXR ] has closed above bottom band by 29.5%. Bollinger Bands are 51% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	9.31 - 9.37	9.37 - 9.42
Low:	8.29 - 8.35	8.35 - 8.4
Close:	9.11 - 9.22	9.22 - 9.3

Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.

Sun, 25 Oct 2026
Daxor Corporation Estimates – NASDAQ:DXR - TradingView

Tue, 20 Oct 2026
Enterprise value to EBIT forward of Daxor Corporation – BOATS:DXR - TradingView

Thu, 15 Oct 2026
Daxor Accelerates Commercial Expansion of Next-Gen Blood - GlobeNewswire

Wed, 14 Oct 2026
Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026 - GlobeNewswire

Tue, 13 Oct 2026
Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 - GlobeNewswire

Mon, 28 Sep 2026
Daxor Corporation (DXR) Shares Advance 3.09% to $11.35 as Buyers Reclaim Ground Below Resistance - Risk Parity Rebalance - siam.in

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	5.84e+006 (%)
Held by Institutions	2.9e+006 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	31360
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.1
Profit Margin	19 %
Operating Margin	861.4 %
Return on Assets (ttm)	-4 %
Return on Equity (ttm)	529.8 %
Qtrly Rev. Growth	14.2 %
Gross Profit (p.s.)	0.09
Sales Per Share	-0.01
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	8.36
Price to Sales	-1.16791e+006
Price to Cash Flow	0

Dividend	6960
Forward Dividend	592
Dividend Yield	75652.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.